Olaparib in Breast Cancer Treatment

Key Features of the OlympiA Trial

• The OlympiA trial was a phase III, double-blind, randomized trial that evaluated the efficacy of adjuvant olaparib in patients with early-stage, HER2-negative breast cancer with high risk of recurrence and germline BRCA1 or BRCA2 mutations 1
• The trial demonstrated that 1 year of adjuvant olaparib following completion of local treatment and (neo)adjuvant chemotherapy significantly improved invasive disease-free survival and distant disease-free survival compared to placebo 1, 2
• At 3 years, invasive disease-free survival was 85.9% in the olaparib group versus 77.1% in the placebo group (HR 0.58; 99.5% CI, 0.41-0.82; P<0.001) 1, 2
• Distant disease-free survival at 3 years was 87.5% in the olaparib group versus 80.4% in the placebo group (HR 0.57; 99.5% CI, 0.39-0.83; P<0.001) 1

Metastatic Setting: OlympiAD Trial

• OlympiAD was a phase III trial that randomized patients with germline BRCA-mutated, HER2-negative metastatic breast cancer to olaparib or chemotherapy treatment of physician's choice 3, 4, 5
• The trial showed significantly improved progression-free survival with olaparib (7.0 months) compared to chemotherapy (4.2 months) (HR 0.58; 95% CI, 0.43-0.80; P<0.001) 3, 5

Clinical Implications

• The American Society of Clinical Oncology recommends that patients with early-stage, HER2-negative breast cancer with germline BRCA1/2 mutations should receive 1 year of adjuvant olaparib after completing standard treatments 6
• For metastatic disease, the National Comprehensive Cancer Network established olaparib as a preferred treatment option for patients with germline BRCA1/2 mutations and HER2-negative breast cancer 3, 4, 5
• PARP inhibitors (olaparib and talazoparib) are now considered category 1 preferred options for patients with germline BRCA1/2 mutations in the metastatic setting 4, 7

Role of Olaparib in Breast Cancer

Metastatic Breast Cancer Setting

• Olaparib is indicated for patients with HER2-negative metastatic breast cancer with germline BRCA1 or BRCA2 mutations who have been previously treated with chemotherapy 8, 9, 10
• Testing for germline BRCA1/2 mutations is essential to identify eligible patients for PARP inhibitor therapy 9, 10
• Patients can receive olaparib in first-line through third-line settings rather than chemotherapy when they are no longer benefiting from endocrine therapy (for hormone receptor-positive disease) 8

Early-Stage Breast Cancer Setting

• For patients with early-stage, HER2-negative breast cancer with high risk of recurrence and germline BRCA1/2 mutations, one year of adjuvant olaparib should be offered after completion of (neo)adjuvant chemotherapy and local treatment 11, 12, 13, 14
• The American Society of Clinical Oncology recommends that for patients who had surgery first, olaparib should be offered if tumor size ≥2 cm or any involved axillary nodes for triple-negative breast cancer, or if at least four involved axillary lymph nodes for hormone receptor-positive disease 13, 14
• The OlympiA trial showed that one year of adjuvant olaparib following completion of local treatment and (neo)adjuvant chemotherapy significantly improved invasive and distant disease-free survival 12, 13, 14

Special Considerations

• PARP inhibitors are DNA-interacting drugs with potential to induce hematologic malignancies; long-term follow-up for myelodysplastic syndrome and acute myelogenous leukemia is needed 13, 14
• In the adjuvant setting, the OlympiA trial did not assess olaparib's efficacy compared to capecitabine in the post-neoadjuvant setting for triple-negative breast cancer 13, 14

Adjuvant Therapy for gBRCA-Positive TNBC with pCR

Rationale for Olaparib

• The American Society of Clinical Oncology (ASCO) recommends that patients with triple-negative breast cancer who have gBRCA1/2 mutations should be offered 1 year of adjuvant olaparib, regardless of whether pathologic complete response (pCR) was achieved, after completing all local treatments including radiation 15, 16, 17
• Olaparib should be given to patients with triple-negative breast cancer and any residual cancer after neoadjuvant chemotherapy, extending to all high-risk patients including those with pCR who had initially locally advanced disease 15, 16
• The OlympiA trial demonstrated significant improvement in invasive disease-free survival at 3 years with olaparib versus placebo (HR 0.58; P<0.001) 15, 16
• The OlympiA trial also showed improvement in distant disease-free survival at 3 years with olaparib versus placebo (HR 0.57; P<0.001) 15, 16

Clinical Algorithm

• The ASCO guideline recommends starting olaparib 300 mg orally twice daily for 1 year after completion of radiation therapy 15, 16
• Patients should be monitored for hematologic toxicities, particularly anemia, while on olaparib 15, 18

Important Considerations

• gBRCA mutation status confers both therapeutic vulnerability to PARP inhibitors and inherent genomic instability that justifies adjuvant olaparib even with pCR 15, 16
• Follow-up for myelodysplastic syndrome and acute myelogenous leukemia is needed given PARP inhibitors are DNA-interacting drugs 15, 17, 18

Adjuvant Olaparib Therapy for Non-Metastatic TNBC with Germline BRCA1/2 Mutations

Patient Selection

• All patients with germline BRCA1/2-mutated, HER2-negative triple-negative breast cancer who meet high-risk criteria should receive 1 year of adjuvant olaparib after completing (neo)adjuvant chemotherapy and locoregional therapy, as recommended by the European Society for Medical Oncology 19

Treatment Outcomes

Eligibility of HER2‑Negative Breast Cancer Subtypes

Tumor Characteristics

• The National Comprehensive Cancer Network (NCCN) specifies that patients with HER2‑negative early breast cancer—encompassing both hormone‑receptor‑positive and triple‑negative subtypes—are eligible for enrollment in the OlympiA trial. 20

Adjuvant Olaparib for High‑Risk HER2‑Negative BRCA‑Mutated Breast Cancer

Dosing, Duration, and Concomitant Endocrine Therapy

• The National Comprehensive Cancer Network (NCCN) recommends administering olaparib 300 mg orally twice daily for a fixed duration of 1 year after completion of local therapy and (neo)adjuvant chemotherapy. Category 1 evidence supports this regimen. 21
• For patients with hormone‑receptor‑positive disease, olaparib should be given concurrently with ongoing endocrine therapy throughout the 1‑year course. 21

Eligibility Requirements (OlympiA Trial Criteria)

• Eligibility requires a germline pathogenic BRCA1 or BRCA2 variant in addition to HER2‑negative status and completion of (neo)adjuvant chemotherapy. The NCCN guideline cites the OlympiA trial as the basis for this criterion. 21

Integration with Other Adjuvant Therapies

• In hormone‑receptor‑positive patients who have ≥ 4 positive axillary nodes and a germline BRCA mutation, the NCCN permits combined use of olaparib (1 year) and abemaciclib (2 years) as adjuvant therapy. Evidence level for this combination is not explicitly graded in the guideline. 21
• For hormone‑receptor‑positive disease, standard endocrine therapy—with or without ovarian suppression for premenopausal patients—remains indicated alongside olaparib. 21
• When high‑risk criteria are met (≥ 4 positive nodes, or 1–3 nodes with additional high‑risk features), NCCN recommends 2 years of adjuvant abemaciclib; this recommendation is independent of olaparib use. 21

Clinical Outcomes (OlympiA Trial)

• The OlympiA Phase III trial, referenced by NCCN, demonstrated a 4‑year overall survival of 89.8 % with olaparib versus 86.4 % with placebo, corresponding to a statistically significant benefit (hazard ratio not specified). This outcome underpins the Category 1 recommendation for adjuvant olaparib. 21

OlympiA Trial Eligibility Criteria

Inclusion Criteria

• The OlympiA trial enrolled adults (≥ 18 years) with HER2‑negative early‑stage breast cancer who carried a germline BRCA1 or BRCA2 pathogenic/likely pathogenic variant confirmed by genetic testing and who met predefined high‑risk clinicopathological features after completing standard local therapy and chemotherapy. [22][23]
• High‑risk clinicopathological features were defined according to hormone‑receptor status:
  
  • Triple‑negative breast cancer (TNBC): tumor size ≥ 2 cm or any involved axillary lymph node, irrespective of whether patients received neoadjuvant or adjuvant chemotherapy. 22
  • Hormone‑receptor‑positive (HR+) disease: presence of ≥ 4 involved axillary lymph nodes. 22
• Participants were required to have completed at least six cycles of (neo)adjuvant chemotherapy before randomization. [22][23]
• 95 % of trial participants received anthracycline‑ and taxane‑based chemotherapy, establishing this regimen as the expected standard background therapy. [22][23]
• All participants must have completed definitive local treatment (surgery and radiation therapy) prior to initiating olaparib. 22

Exclusion Criteria (Inferred from Trial Design)

• Patients with HER2‑positive breast cancer were excluded, as the trial required HER2‑negative disease. 22
• Metastatic disease at enrollment disqualified patients, given the focus on early‑stage cancer. 22
• Individuals lacking a germline BRCA1/2 pathogenic or likely pathogenic variant (including those with only somatic mutations) were not eligible. 22
• Failure to meet the minimum chemotherapy requirement of at least six cycles resulted in exclusion. [22][23]
• Incomplete local therapy (surgery or radiation) at the time of randomization excluded patients. 22